Business Description
Alkermes PLC
NAICS : 325412
SIC : 2834
ISIN : IE00B56GVS15
Share Class Description:
ALKS: Ordinary SharesTotal Employee Number:
2,050Compare
Compare
Traded in other countries / regions
ALKS.USA8AK.Germany Index Membership
Russell 2000Russell 3000 IPO Date
1991-07-16Description
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.42 | |||||
Equity-to-Asset | 0.41 | |||||
Debt-to-Equity | 0.87 | |||||
Debt-to-EBITDA | 7.21 | |||||
Interest Coverage | 2.43 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.27 | |||||
Beneish M-Score | -1.43 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 8.8 | |||||
3-Year EBITDA Growth Rate | 75.1 | |||||
3-Year EPS without NRI Growth Rate | 61.4 | |||||
3-Year Book Growth Rate | 20 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 11.81 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.63 | |||||
9-Day RSI | 36.3 | |||||
14-Day RSI | 38.49 | |||||
3-1 Month Momentum % | 12.68 | |||||
6-1 Month Momentum % | 78.08 | |||||
12-1 Month Momentum % | 83.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.3 | |||||
Quick Ratio | 1.85 | |||||
Cash Ratio | 0.99 | |||||
Days Inventory | 344.52 | |||||
Days Sales Outstanding | 80.63 | |||||
Days Payable | 147.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.2 | |||||
Shareholder Yield % | -8.39 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 84.56 | |||||
Operating Margin % | 8.62 | |||||
Net Margin % | 3.97 | |||||
EBITDA Margin % | 13.08 | |||||
FCF Margin % | 13.29 | |||||
OCF Margin % | 15.06 | |||||
ROE % | 3.78 | |||||
ROA % | 2.1 | |||||
ROIC % | 5.16 | |||||
3-Year ROIIC % | 44.94 | |||||
ROC (Joel Greenblatt) % | 25.41 | |||||
ROCE % | 6.05 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 120.97 | |||||
Forward PE Ratio | 61.36 | |||||
PE Ratio without NRI | 97.6 | |||||
Price-to-Owner-Earnings | 437.85 | |||||
PS Ratio | 4.68 | |||||
PB Ratio | 4.26 | |||||
Price-to-Free-Cash-Flow | 36.14 | |||||
Price-to-Operating-Cash-Flow | 31.82 | |||||
EV-to-EBIT | 55.16 | |||||
EV-to-Forward-EBIT | 12.53 | |||||
EV-to-EBITDA | 39.57 | |||||
EV-to-Forward-EBITDA | 11.5 | |||||
EV-to-Revenue | 5.17 | |||||
EV-to-Forward-Revenue | 4.53 | |||||
EV-to-FCF | 38.93 | |||||
Price-to-GF-Value | 1.42 | |||||
Price-to-Projected-FCF | 2.13 | |||||
Price-to-Median-PS-Value | 1.36 | |||||
Price-to-Peter-Lynch-Fair-Value | 3.9 | |||||
Earnings Yield (Greenblatt) % | 1.81 | |||||
FCF Yield % | 2.87 | |||||
Forward Rate of Return (Yacktman) % | 23.2 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALKS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alkermes PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,667.652 | ||
| EPS (TTM) ($) | 0.38 | ||
| Beta | 0.4275 | ||
| 3-Year Sharpe Ratio | 0.56 | ||
| 3-Year Sortino Ratio | 1.07 | ||
| Volatility % | 46.15 | ||
| 14-Day RSI | 38.49 | ||
| 14-Day ATR ($) | 1.479055 | ||
| 20-Day SMA ($) | 47.9905 | ||
| 12-1 Month Momentum % | 83.44 | ||
| 52-Week Range ($) | 26.4 - 55.67 | ||
| Shares Outstanding (Mil) | 167.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alkermes PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alkermes PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-25 08:00 | In 168 days | ||
| Annual report for 2026 | 2027-02-25 | In 167 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-25 | In 167 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-28 08:00 | In 48 days | ||
| Third quarter earnings results for 2026 | 2026-10-28 | In 47 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-28 08:00 | 52.73 (-0.27%) | ||
| Second quarter earnings results for 2026 | 2026-07-28 | 52.73 (-0.27%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-10 10:00 | 44.29 (+2.17%) | ||
| General meeting for 2026 | 2026-05-20 14:00 | 37.00 (-0.16%) | ||
| First quarter earnings conference call for 2026 | 2026-05-05 08:00 | 34.17 (+2.92%) |
Show
Entries
Alkermes PLC Frequently Asked Questions
What is Alkermes PLC(ALKS)'s stock price today?
The current price of ALKS is $45.97. The 52 week high of ALKS is $55.67 and 52 week low is $26.40.
When is next earnings date of Alkermes PLC(ALKS)?
The next earnings date of Alkermes PLC(ALKS) is 2026-10-28 Est..
Does Alkermes PLC(ALKS) pay dividends? If so, how much?
Alkermes PLC(ALKS) does not pay dividend.
Guru Commentaries on NAS:ALKS
2026 Q2
baird-small-mid-cap-growth-equity-fund-2026-q2
What the manager wrote
Alkermes is positioned as a leader in the Orexin receptor category, which presents promising growth potential in wakefulness and potentially other indications. The company is one of the few with a lead product in this area, indicating a strong competitive advantage. The addition of Alkermes to our portfolio reflects our belief in its growth trajectory and the potential for significant value creation in the healthcare sector.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers